Month: February 2022

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Monday, March 7, 2022 at 9:10 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following the event. About Entrada Therapeutics Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by...

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 8998936. The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at www.jouncetx.com. The webcast will...

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Technical Officer, Patrick Kleyn, Ph.D., to Senior Vice President and Head of Translational Research and Development, and Elisabeth Crönert-Bendell, M.D., to Senior Vice President and Head of Strategy. “We are pleased to announce the promotions of three exceptionally talented and influential leaders on Rhythm’s executive leadership team,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “Joe, Patrick and Elisabeth continue to play vital roles in our efforts to build a global organization, deliver IMCIVREE® (setmelanotide) to...

Figure 1 Santa Cruz Phase 1 Product Information Bulletins.VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) — South Star Battery Metals Corp. (“South Star” or the “Company”) (TSXV: STS) (OTCQB: STSBF), is pleased to announce that it has received approval from the Brazilian Mining Authority (“ANM”) on February 22th, 2022 of the final exploration reports for the remaining 6 of the 13 claims of the Santa Cruz Graphite Mine in Brazil. In addition, the Company has launched Product Information Bulletins (“PIBs”) for a range of concentrate products for Phase 1 operations. The approval of the Final Exploration Reports for all 13 claims totaling approximately 13,000 hectares is presented in Table 1. The other 7 claims had the final exploration reports previously approved on February 8th, 2022 (See February 9th, 2022 Press Release).Claim...

Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel as part of the National Institutes of Health (NIH) Rare Disease Day® virtual conference on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST. The panel, “Successful Clinical Trial Enrollment with True Advocacy Collaboration During Challenging Times,” will discuss strategies for clinical trial recruitment successes, including lessons learned from aTyr’s experience conducting a Phase 1b/2a study of efzofitimod (ATYR1923) in patients...

Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment CAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment. Ariana Pharma’s proprietary KEM® (Knowledge Extraction and Management) eXplainable Artificial Intelligence (xAI) technology aims at significantly increasing success rates and accelerating...

Philanthropic program gives back to local communities worldwideibex Celebrates 5-Year Anniversary of ibex Cares ibex Celebrates 5-Year Anniversary of ibex Cares.WASHINGTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, is celebrating the 5-year anniversary of ibex Cares, the company’s global philanthropic program that supports local communities where the company operates. This year, the program will be responsible for giving more than $250,000 in donations to local charities and causes. ibex is committed to meaningfully investing in its employees and the communities where they live and work. Employees themselves choose the local charities they want to support and strive to make a difference in the lives of the...

Company’s partnership with Mighty Oak Medical for 3D printed, patient-specific technology continues advancing pediatric scoliosis treatment WARSAW, Ind., Feb. 23, 2022 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the 1,000th case performed with the FIREFLY® Pedicle Screw Navigation Guides (“FIREFLY”) technology in collaboration with Mighty Oak Medical. FIREFLY, which is frequently used in conjunction with OrthoPediatrics’ RESPONSE™ Spine System, provides increased efficiency by utilizing data-driven, pre-surgical planning for optimizing size and trajectory of the pedicle screws when performing complex spinal surgeries. The 3D printed patient-specific guides reduce the need for intraoperative...

NORWALK, Conn., Feb. 23, 2022 (GLOBE NEWSWIRE) — FactSet (NYSE:FDS) (NASDAQ:FDS) and BlackRock (NYSE:BLK) today announced that they have entered into a multi-year partnership to integrate Portware’s execution management system (EMS) capabilities with the Aladdin® platform, BlackRock’s end-to-end investment management and operations platform. The joint offering will provide common clients with a seamless experience across multi-asset portfolio and risk management, and trading execution, including access to Portware’s high-performance electronic trading and automation capabilities via API. FactSet’s Portware is best known in the listed assets and Foreign Exchange markets, and recently added fixed income trading capabilities; and the Aladdin® platform is leveraged by BlackRock and Aladdin clients to power informed decision-making...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. Dr. Kharazi co-invented Bria-IMT™, BriaCell’s lead clinical candidate, in collaboration with Dr. Charles L. Wiseman, BriaCell’s Founder and Principal Research Advisor. Dr. Kharazi currently serves as Chief Technology Officer at Stemedica Cell Technologies, Inc. His experience includes roles as Chief Scientist of the Immunotherapy laboratory at St. Vincent Medical Center in Los Angeles (1998-2006) and Chief Pathologist of a...